Tissue-cultured smallpox vaccine shows promiseMarch 13th, 2009 - 3:27 pm ICT by IANS
Tokyo, March 13 (IANS) A tissue-cultured smallpox vaccine can show an effective response with no serious adverse events, according to a new study.
“The threat of smallpox bioterrorism has prompted reconsideration of the need for smallpox vaccination. Serious adverse events associated with first-generation vaccines such as the New York City Board of Health (Dryvax), Lister, and Ikeda strains have raised obstacles to vaccination campaigns in the United States,” the study authors wrote.
“Developing a vaccine that is safer than first-generation vaccines yet highly immunogenic (producing immunity or an immune response) is crucial to constructing a prevention plan in the event of bioterrorist attack,” they added.
Tomoya Saito, Keio University, Tokyo, and colleagues examined the clinical and immunological responses to the LC16m8 vaccine in adults who had been previously vaccinated and in those who had not.
LC16m8 is a live, attenuated (reduced in strength), tissue-cultured third-generation vaccine that was administered to more than 100,000 infants in Japan between 1973 and the beginning of 1976.
The adults in this study, who are in the Japan Self-Defence Forces, received the LC16m8 vaccine between 2002 and 2005. Vaccinees were examined 10 to 14 days after vaccination to determine if they had developed a major skin reaction (a measure of immune response, known as take). The researchers monitored vaccinees for adverse events for 30 days after the vaccination.
They found that administration of the vaccine was associated with high levels of seroconversion (development of antibodies) in adults who were not previously vaccinated and yielded an effective booster response in some previously vaccinated individuals, a Keio University release said.
Seroconversion or an effective booster response among the individuals with take was elicited in 37 of 41 (90.2 percent) participants who had not been vaccinated before and in 93 of 155 (60.0 percent) previously vaccinated participants.
The overall proportion of clinical take was significantly higher in primary vaccinees (94.4 percent) than in revaccinees (86.6 percent).
These findings were published in Wednesday’s issue of Journal of the American Medical Association.
- FACTSHEETS - Smallpox: in detail - Mar 25, 2010
- Poor sleep hits potency of vaccines - Aug 02, 2012
- PFCs weaken immune response to vaccine shots in childhood - Jan 25, 2012
- Potent new vaccine found effective against Alzheimer's - Jun 08, 2012
- 1.4 bn at rabies risk in Southeast Asia: WHO - Sep 27, 2011
- Modified yellow fever vaccine may help fight malaria - Jun 12, 2010
- Kids respond better to recommended swine flu vaccine - May 28, 2010
- Vaccine response could depend on your sex - May 13, 2010
- Vaccine-delivering nanoparticles may help fight HIV, malaria - Feb 23, 2011
- Stress can be good for immune system - Jun 22, 2012
- New meningitis vaccine could save thousands - Jun 10, 2011
- Super vaccine could knock out 70 percent of cancers - Dec 13, 2011
- Soon, nasal spray vaccine to fight Alzheimer's, stroke - Mar 01, 2011
- Stem cells from embryo sac could heal damaged hearts - May 29, 2010
- Swine flu spread much wider than suspected - Jun 09, 2011
Tags: attenuated, board of health, defence forces, generation vaccine, generation vaccines, immune response, immunological responses, keio university, new york city board of health, prevention plan, serious adverse events, skin reaction, smallpox vaccination, smallpox vaccine, study authors, threat of smallpox, tokyo march, tomoya, vaccinated individuals, vaccination campaigns